Inovio End Period Cash Flow from 2010 to 2024

INO Stock  USD 4.19  0.18  4.49%   
Inovio Pharmaceuticals End Period Cash Flow yearly trend continues to be very stable with very little volatility. End Period Cash Flow is likely to drop to about 13.6 M. During the period from 2010 to 2024, Inovio Pharmaceuticals End Period Cash Flow quarterly data regression pattern had sample variance of 3650 T and median of  23,693,633. View All Fundamentals
 
End Period Cash Flow  
First Reported
1999-03-31
Previous Quarter
34.4 M
Current Value
21.7 B
Quarterly Volatility
2.1 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 1.2 M or Total Revenue of 790.4 K, as well as many indicators such as Price To Sales Ratio of 155, Dividend Yield of 1.0E-4 or PTB Ratio of 1.1. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Latest Inovio Pharmaceuticals' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Inovio Pharmaceuticals over the last few years. It is Inovio Pharmaceuticals' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inovio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Pretty Stable
   End Period Cash Flow   
       Timeline  

Inovio End Period Cash Flow Regression Statistics

Arithmetic Mean43,067,522
Geometric Mean26,162,828
Coefficient Of Variation140.28
Mean Deviation33,808,515
Median23,693,633
Standard Deviation60,415,034
Sample Variance3650T
Range245.1M
R-Value0.25
Mean Square Error3682.3T
R-Squared0.06
Significance0.37
Slope3,396,003
Total Sum of Squares51099.7T

Inovio End Period Cash Flow History

202413.6 M
202314.3 M
202246.3 M
202171.1 M
2020250.7 M
201922.2 M
201823.7 M

About Inovio Pharmaceuticals Financial Statements

Inovio Pharmaceuticals investors utilize fundamental indicators, such as End Period Cash Flow, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow14.3 M13.6 M
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.43)
Revenue Per Share
0.025
Quarterly Revenue Growth
(0.55)
Return On Assets
(0.40)
Return On Equity
(0.91)
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.